Innocrin was formed as a spin-out of the oncology-focused assets from Viamet Pharmaceuticals in October, 2014. Innocrin is developing novel, best-in-class oral inhibitors of CYP17 lyase, an enzyme involved in the production of androgens and estrogen. Lowering androgen levels is a clinically validated method of treating prostate cancer, and may also provide potential benefit in treating some patients with breast cancer as well as non-oncologic syndromes that are due to hormonal excess, like endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
ArtusLabs is a technology company that enables scientific data management and workplace collaboration for research-driven entities such as biotech companies, pharmaceutical companies, and academic institutes and laboratories. Blending together the management of unstructured information and insights with social networking, personal publication, and refined data mining, ArtusLabs can significantly enhance internal and external research communication and research management. The company’s “Genius” product line provides significant innovation for selecting optimal purifications, formulations, reactions, and other activities. In March 2011, Perkin Elmer acquired Artus Labs.
Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products through a proprietary ocular microinjection platform that targets the individual compartments of the eye. Currently, Clearside Biomedical is focused on its initial product candidate, CLS1001, under development for retinal applications through the delivery of proven therapeutics to the suprachoroidal space. Clearside Biomedical was founded by an executive team with extensive development and revenue growth expertise, focused on improving the delivery of therapeutic agents to improve standard of care for patients with sight threatening disease.
Device Innovation Group
Device Innovation Group (“DIG”) was founded in 2011 as the result of a partnership between medical device company MDI Partners and two venture capital firms, TriStar Technology Fund and Limestone Fund. The company’s mission is to develop early stage medical devices that fulfill unmet clinical needs and underserved markets that are often overlooked by larger investment firms. DIG will incorporate a “fail fast” philosophy and a strategy of rapid advancement, welcoming new innovation from various sources including universities, hospitals and entrepreneurs.
Clinipace is a digital clinical research organization (dCRO), providing technology-driven clinical services for phase I-IV clinical trials and registries, serving biopharmaceutical and medical device companies as well as academic medical centers. Clinipace is built on TEMPOTM, an integrated EDC and Study Management platform integrating the core functional needs of clinical studies or grant management programs — Clinical Data Capture, Study Management, and Grant Tracking into a single, highly scalable, easy to use platform.
Embrella Cardiovascular, Inc., is developing an embolic protection device called the Embrella Embolic DeflectorTM. A large growth market exists related to percutaneous aortic valve replacement (PAVR), a relatively new procedure that involves non-surgical, catheter-based implantation of a replacement aortic valve for the treatment of aortic stenosis. During the PAVR procedure, a major complication is the increased incidence of stroke from debris dislodging from the diseased aortic valve. The Embrella device acts as a filter/deflector for these potential emboli by positioning it at the origin of the carotid arteries. In March 2011, Edwards Lifesciences acquired Embrella.
GeneCentric Diagnostics was founded in 2011 by Chuck Perou, Ph.D. and Neil Hayes, MD from The University of North Carolina at Chapel Hill, and Myla Lai-Goldman, MD. GeneCentric is focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients to make more informed, individualized treatment decisions. GeneCentric brings together innovative science solving today’s critical interpretive needs with experts in diagnostics and is led by Myla Goldman, MD, former chief medical and scientific officer of LabCorp.
Histosonics is a medical device company that has developed a system for treating BPH through histotripsy, a non-invasive, image guided, robotically controlled system for precise tissue ablation. In addition to BPH treatment and prostate cancer ablation, histotripsy is applicable to many other diseases including non-invasive solid tumor ablation and thrombolysis for deep vein thrombosis.
Pathfinder is a medical device company dedicated to increasing the number and effectiveness of surgeries on abdominal and other soft tissue organs. Pathfinder is the first company to receive FDA clearance for a medical device to navigate liver surgery using preoperative medical images. Pathfinder’s products, Explorer and Scout, improve surgical precision by allowing surgeons to “see through” the organ they are operating on by registering the surgical instrument in three-dimensional space onto pre-operative patient medical images. These products will eventually allow surgeons to perform minimally invasive abdominal procedures.
PhaseBio is a biopharmaceutical company applying a flexible new platform for biological drugs (peptides and proteins) based on the use of elastin-like polypeptides (ELP’s). PhaseBio’s engineered proteins and peptides have improved manufacturing, pharmacokinetic, and pharmacodynamic properties. The company’s lead programs in phenylketonuria (PKU), diabetes, and respiratory diseases are entering clinical trials.
SpineAlign is a medical device company that has developed an implantable device to treat vertebral compression fractures. The company has received a CE Mark and has completed a 50 patient study in Europe. The company’s device shows the ability to restore height and reduce pain. The U.S. trial and 501(k) process is commencing.
TetraLogic Pharmaceuticals is a biopharmaceutical company that discovers and develops small molecule drugs
that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company’s Smac Mimetics neutralize the activity of key Inhibitor of Apoptosis Proteins allowing pro-apoptotic signals delivered from cancer therapies and the tumor microenvironment to destroy cancer cells.
Viamet is discovering new drugs that inhibit metalloenzymes. Metalloenzymes are targeted by 10% of all currently approved drugs. Using a proprietary drug discovery platform, Viamet can design drugs with improved efficacy and safety properties. The company’s lead programs in fungal disease and hormone resistant prostate cancer are at candidate selection stage.